Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | PBRM1 | Q86U86 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 4/20 | 0.33 |
| ▸ | RAB9A | P51151 | 3/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | XBP1 | P17861 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1751285 | 1.00 | CA12 (0.40) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL4973069 | 0.91 | CA12 (0.35) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL4973073 | 0.91 | CA12 (0.35) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL7550008 | 0.88 | CA12 (0.38) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL7550001 | 0.88 | CA12 (0.38) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL10518873 | 0.88 | CA12 (0.38) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL23846798 | 0.84 | CA12 (0.36) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL5802805 | 0.84 | SMN1; SMN2 (0.36) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL26503771 | 0.84 | CA12 (0.36) | CA12CA1CA2ESR1CA9 | |
| SCHEMBL5802808 | 0.84 | SMN1; SMN2 (0.36) | CA12CA1CA2ESR1CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968720-B2 | Secondary amines as renin inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-06-28 | — | — | US | disclosed |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-07-09 | — | — | US | disclosed |
| US-20090062342-A1 | AMINES | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-03-05 | — | — | US | disclosed |
| EP-1994026-A2 | NEW AMINES | Actelion Pharmaceuticals Ltd. (CH) | 2008-11-26 | — | — | EP | disclosed |
| EP-1981847-A1 | SECONDARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2008-10-22 | — | — | EP | disclosed |
| US-7432256-B2 | Substitued imidazo [1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2008-10-07 | — | — | US | disclosed |
| EP-1828194-B1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | HOFFMANN LA ROCHE (CH) | 2008-05-28 | — | — | EP | disclosed |
| WO-2007102127-A2 | NEW AMINES | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-13 | — | — | WO | disclosed |
| EP-1828194-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F. Hoffmann-Roche AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2007088514-A1 | SECONDARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-08-09 | — | — | WO | disclosed |
| WO-2006131884-A2 | THIAZOLE SUBSTITUTED DIAZABICYCLONONANE OR-NONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-12-14 | — | — | WO | disclosed |
| WO-2006063610-A1 | HETEROARYL SUBSTITUTED DIAZABICYCLONONENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006063708-A1 | TETRACYCLIC IMIDAZO-BENZODIAZEPINES AS GABA RECEPTORS MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-06-22 | — | — | WO | disclosed |
| WO-2006064484-A1 | AZABICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2006-06-22 | — | — | WO | disclosed |
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | HOFFMANN-LA ROCHE INC. | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128691-A1 | Substituted imidazo[1,5-A][1,2,4]triazolo[1,5-D][1,4]benzodiazepine derivatives | GABRA3, GABRA5, GABRA1 | CA12 2796/4885CA1 591/4885CA2 1003/4885 |
| US-20090062342-A1 | AMINES | REN, ACE, MAOA | CA12 3467/4885CA1 3629/4885CA2 1597/4885 |
| US-20090176823-A1 | Secondary Amines as Renin Inhibitors | REN, ACE, AGTR1 | CA12 3222/4885CA1 3341/4885CA2 1133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.